Jury awards Centocor $1.7B in patent case against Abbott - San Francisco Business Times:

firukendu-anchored.blogspot.com
An Abbott spokesman said the companywill appeal. Pa.-based Centocor, a division of (NYSE:JNJ), makezs the blockbuster rheumatoid arthritistreatmentf Remicade, and had sued Abbott over Abbott’w arthritis drug, Humira. Both are so-called anti-TNF arthritis Horsham, Pa.-based Centocor said it is the exclusivew licensee ofthe patent, which is co-owned by . Centocotr President Kim Taylorsaid “thed jury recognized our valuable intellectualo property, finding our patent both valid and infringed.
We will continue to assert intellectual property rights for ourimmunologhy therapies, as they offer significant advances in treatment for patientx with a number of immune mediaterd inflammatory diseases.” Abbott spokesman Scott E. Stoffel said, “We are disappointee in this verdict, and we are confident in the merits of our case and that we will prevaiklon appeal. “The evidence clearl established that Humira was the firsy ofits kind, fully-human anti-TNF antibodty medicine,” Stoffel said. “JNJ’s anti-TNF antibody medication, is partially made from mouser DNA. JNJ did not launchb a fully-human product until Aprill 2009.
In fact, only when Humira was nearing its approval in 2002 did JNJ amendc the patent at issue in this litigation to claimm that it haddiscovered fully-human antibodiesz in 1994. JNJ acknowledged at trial that it did not starft working ona fully-human antibody until 1997 — two years afterf Abbott discovered Humira and one year afterr Abbott filed its patent application s for Humira.”